
Please try another search
Needham & Company upgraded shares of Hologic (NASDAQ:HOLX) to Buy from Hold, assigning a price target of $95 per share in a note Friday.
Analysts told investors that easing Covid testing headwinds will unmask growth drivers for the company.
"We think the COVID-related headwind will soon end and that HOLX can grow at least at its 5-7% organic ex-COVID growth target," they explained.
"Additionally, we foresee potential for above-normal non-COVID Diagnostics, Breast Health, and GYN Surgical growth in the next few quarters. We also believe that HOLX can drive ~50+ bps of annual operating margin improvement and 8-12% EPS growth," they added.
The analysts concluded that based on the growth profile and HOLX's P/E of 20.2x, Needham's CY2023 estimate, they believe that the company's shares are undervalued.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.